Anti-oxidative stress response genes: Bioinformatic analysis of their expression and relevance in multiple cancers

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2577-2590

  Rotblat, Barak ^a   Grunewald, Thomas G P ^b   Leprivier, Gabriel ^c   Melino, Gerry ^a,d   Knight, Richard A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUT CURIE   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti oxidant genes; Breast cancer; G6PD; Glutathione; Lung cancer; NRF2; Thioredoxin

Indexed keywords

GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BIOINFORMATICS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MULTIPLE CANCER; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; TUMOR MICROENVIRONMENT;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; TUMOR MICROENVIRONMENT;

EID: 84891950598     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1658     Document Type: Article

References (137)

1. Cairns RA, Harris IS and Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95.
2. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013; 153(5):1064-1079.
3. Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308.
4. Grunewald TG, Herbst SM, Heinze J and Burdach S. Understanding tumor heterogeneity as functional compartments--superorganisms revisited. Journal of translational medicine. 2011; 9:79.
5. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J and Rich JN. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2013.
6. Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S, Romano S, Romano MF, Sagar V, Loreni F, Landriscina M and Esposito F. Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. Cell death&disease. 2013; 4:e851.
7. Jeon SM, Chandel NS and Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012; 485(7400):661-665.
8. Sanchez-Macedo N, Feng J, Faubert B, Chang N, Elia A, Rushing EJ, Tsuchihara K, Bungard D, Berger SL, Jones RG, Mak TW and Zaugg K. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ. 2013; 20(4):659-668.
9. Trachootham D, Alexandre J and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009; 8(7):579-591.
10. Schweikert EM, Devarajan A, Witte I, Wilgenbus P, Amort J, Forstermann U, Shabazian A, Grijalva V, Shih DM, Farias-Eisner R, Teiber JF, Reddy ST and Horke S. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell death and differentiation. 2012; 19(9):1549-1560.
11. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, He Q, Chen J, Xu HG, Zhao RX, Werle KD, Cui R, Liang J, Li YL and Xu ZX. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis. 2013; 4:e824.
12. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nature reviews Drug discovery. 2013; 12(12):931-947
13. Shelton P and Jaiswal AK. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? Faseb J. 2013; 27(2):414-423.
14. Joo MS, Lee CG, Koo JH and Kim SG. miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury. Cell death&disease. 2013; 4:e899.
15. Shah NM, Rushworth SA, Murray MY, Bowles KM and MacEwan DJ. Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget. 2013; 4(8):1130-1142.
16. Antonov AV, Schmidt T, Wang Y and Mewes HW. ProfCom: a web tool for profiling the complex functionality of gene groups identified from high-throughput data. Nucleic Acids Res. 2008; 36(Web Server issue):W347-351.
17. Serrano M and Blasco MA. Cancer and ageing: convergent and divergent mechanisms. Nature reviews Molecular cell biology. 2007; 8(9):715-722.
18. Antonov AV, Schmidt EE, Dietmann S, Krestyaninova M and Hermjakob H. R spider: a network-based analysis of gene lists by combining signaling and metabolic pathways from Reactome and KEGG databases. Nucleic Acids Res. 2010; 38(Web Server issue):W78-83.
19. Foller M, Harris IS, Elia A, John R, Lang F, Kavanagh TJ and Mak TW. Functional significance of glutamate-cysteine ligase modifier for erythrocyte survival in vitro and in vivo. Cell death and differentiation. 2013; 20(10):1350-1358.
20. Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res. 2011; 39(Web Server issue):W323-327.
21. Dalleau S, Baradat M, Gueraud F and Huc L. Cell death and diseases related to oxidative stress:4-hydroxynonenal (HNE) in the balance. Cell death and differentiation. 2013; 20(12):1615-1630.
22. Song Z, Saghafi N, Gokhale V, Brabant M and Meuillet EJ. Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster. Experimental cell research. 2007; 313(6):1161-1171.
23. Bassi C and Stambolic V. PTEN, here, there, everywhere. Cell death and differentiation. 2013; 20(12):1595-1596.
24. Li C, Thompson MA, Tamayo AT, Zuo Z, Lee J, Vega F, Ford RJ and Pham LV. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget. 2012; 3(3):314-326.
25. Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH and Cho JY. Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World journal of gastroenterology: WJG. 2012; 18(39):5581-5588.
26. Noike T, Miwa S, Soeda J, Kobayashi A and Miyagawa S. Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer. Hum Pathol. 2008; 39(2):201-208.
27. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC and Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res. 2001; 7(10):3087-3091.
28. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenfuhrer J, Baumbach JI, Sickmann A, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast cancer research: BCR. 2010; 12(3):R44.
29. Zhu X, Huang C and Peng B. Overexpression of thioredoxin system proteins predicts poor prognosis in patients with squamous cell carcinoma of the tongue. Oral oncology. 2011; 47(7):609-614.
30. Kim JH, Bogner PN, Ramnath N, Park Y, Yu J and Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007; 13(13):3875-3882.
31. Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, Lee S, Lee C, Ko JJ and An HJ. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. Journal of proteome research. 2010; 9(1):451-457.
32. Woolston CM, Storr SJ, Ellis IO, Morgan DA and Martin SG. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2011; 100(2):308-313.
33. Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q and Ye Q. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. International journal of molecular medicine. 2012; 29(5):832-840.
34. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS and Chi LM. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. Journal of proteome research. 2011; 10(11):4935-4947.
35. Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L and Richards DA. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Investigational new drugs. 2012; 30(4):1591-1596.
36. Baker AF, Adab KN, Raghunand N, Chow HH, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL and Dragovich T. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Investigational new drugs. 2013; 31(3):631-641.
37. Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arner ES and Wiman KG. APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell death&disease. 2013; 4:e881.
38. Gromer S, Arscott LD, Williams CH, Jr., Schirmer RH and Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem. 1998; 273(32):20096-20101.
39. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013; 4(4):502-530.
40. Canas A, Lopez-Sanchez LM, Valverde-Estepa A, Hernandez V, Fuentes E, Munoz-Castaneda JR, Lopez-Pedrera C, De La Haba-Rodriguez JR, Aranda E and Rodriguez-Ariza A. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast cancer research: BCR. 2012; 14(6):R153.
41. Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S, Meng J, Ji L, Coombes K, Minna JD, Fang B and Roth JA. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 2013; 73(17):5532-5543.
42. Chandler JD, Nichols DP, Nick JA, Hondal RJ and Day BJ. Selective metabolism of hypothiocyanous acid by mammalian thioredoxin reductase promotes lung innate immunity and antioxidant defense. J Biol Chem. 2013; 288(25):18421-18428.
43. Fath MA, Ahmad IM, Smith CJ, Spence J and Spitz DR. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res. 2011; 17(19):6206-6217.
44. Fricker SP. Strategies for the biological evaluation of gold anticancer agents. Anti-cancer agents in medicinal chemistry. 2011; 11(10):940-952.
45. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM and Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxidative medicine and cellular longevity. 2013; 2013:972913.
46. Calvert P, Yao KS, Hamilton TC and O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact. 1998; 111-112:213-224.
47. Estrela JM, Ortega A and Obrador E. Glutathione in cancer biology and therapy. Critical reviews in clinical laboratory sciences. 2006; 43(2):143-181.
48. Sceneay J, Liu MC, Chen A, Wong CS, Bowtell DD and Moller A. The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo. PLoS One. 2013; 8(6):e66388.
49. Jardim BV, Moschetta MG, Leonel C, Gelaleti GB, Regiani VR, Ferreira LC, Lopes JR and de Campos Zuccari DA. Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study. Oncology reports. 2013; 30(3):1119-28. doi: 10.3892/or.2013.2540.
50. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54(16):4313-4320.
51. Boivin A, Hanot M, Malesys C, Maalouf M, Rousson R, Rodriguez-Lafrasse C and Ardail D. Transient alteration of cellular redox buffering before irradiation triggers apoptosis in head and neck carcinoma stem and non-stem cells. PLoS One. 2011; 6(1):e14558.
52. Benassi B, Marani M, Loda M and Blandino G. USP2a alters chemotherapeutic response by modulating redox. Cell death&disease. 2013; 4:e812.
53. Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M and Cullen KJ. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999; 5(12):4097-4104.
54. Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R and Cullen KJ. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res. 2008; 14(18):5877-5883.
55. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H and Johnston PG. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998; 4(6):1469-1474.
56. Tan KL, Jankova L, Chan C, Fung CL, Clarke C, Lin BP, Robertson G, Molloy M, Chapuis PH, Bokey L, Dent OF and Clarke SJ. Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology. 2011; 59(6):1057-1070.
57. Jardim BV, Moschetta MG, Gelaleti GB, Leonel C, Regiani VR, de Santi Neto D, Bordin-Junior NA, Perea SA and Zuccari DA. Glutathione transferase pi (GSTpi) expression in breast cancer: an immunohistochemical and molecular study. Acta histochemica. 2012; 114(5):510-517.
58. Huang J, Tan PH, Thiyagarajan J and Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2003; 16(6):558-565.
59. Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH and Massuger LF. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer epidemiology, biomarkers&prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009; 18(8):2176-2181.
60. Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell death and differentiation. 2010; 17(9):1373-1380.
61. Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O and Karihtala P. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Experimental hematology&oncology. 2012; 1(1):2.
62. Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MI, Combs GF, Jr. and Diamond AM. Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. The Prostate. 2012; 72(9):1006-1012.
63. Ho JC, Chan-Yeung M, Ho SP, Mak JC, Ip MS, Ooi GC, Wong MP, Tsang KW and Lam WK. Disturbance of systemic antioxidant profile in nonsmall cell lung carcinoma. The European respiratory journal. 2007; 29(2):273-278.
64. Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem. 1982; 257(22):13704-13712.
65. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1994; 12(1):194-205.
66. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH and Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002; 8(12):3658-3668.
67. Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, Spitz DR, Knudson CM and Simons AL. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One. 2012; 7(10):e48175.
68. Moinova HR and Mulcahy RT. Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun. 1999; 261(3):661-668.
69. Wild AC, Moinova HR and Mulcahy RT. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem. 1999; 274(47):33627-33636.
70. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. The Journal of biological chemistry. 2000; 275(21):16023-16029.
71. Chan JY and Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta. 2000; 1517(1):19-26.
72. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-322.
73. Kensler TW, Wakabayashi N and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual review of pharmacology and toxicology. 2007; 47:89-116.
74. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012; 22(1):66-79.
75. Lim JH, Kim KM, Kim SW, Hwang O and Choi HJ. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacological research: the official journal of the Italian Pharmacological Society. 2008; 57(5):325-331.
76. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM and Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. The Journal of biological chemistry. 1999; 274(37):26071-26078.
77. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M and Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem. 2001; 276(21):18399-18406.
78. Kim YC, Yamaguchi Y, Kondo N, Masutani H and Yodoi J. Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene. 2003; 22(12):1860-1865.
79. Heasman SA, Zaitseva L, Bowles KM, Rushworth SA and Macewan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget. 2011; 2(9):658-668.
80. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M and Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis. 2003; 24(3):461-467.
81. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P and Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(11):7610-7615.
82. Jeong WS, Jun M and Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxidants&redox signaling. 2006; 8(1-2):99-106.
83. Baird L and Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Archives of toxicology. 2011; 85(4):241-272.
84. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in biochemical sciences. 2009; 34(4):176-188.
85. Hayes JD, McMahon M, Chowdhry S and Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010; 13(11):1713-1748.
86. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacological research: the official journal of the Italian Pharmacological Society. 2008; 58(5-6):262-270.
87. Rotblat B, Melino G and Knight RA. NRF2 and p53: Januses in cancer? Oncotarget. 2012; 3(11):1272-1283.
88. Satoh H, Moriguchi T, Takai J, Ebina M and Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 2013; 73(13):4158-4168.
89. Taguchi K, Motohashi H and Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes to cells: devoted to molecular&cellular mechanisms. 2011; 16(2):123-140.
90. Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox biology. 2013; 1(1):45-49.
91. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA and Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(4):1433-1438.
92. Koo CY, Muir KW and Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012; 1819(1):28-37.
93. De Craene B, Denecker G, Vermassen P, Taminau J, Mauch C, Derore A, Jonkers J, Fuchs E and Berx G. Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential. Cell death and differentiation. 2013; doi: 10.1038/cdd.2013.148.
94. Wang M and Gartel AL. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget. 2011; 2(12):1218-1226.
95. Halasi M and Gartel AL. Targeting FOXM1 in cancer. Biochemical pharmacology. 2013; 85(5):644-652.
96. Gartel AL. The oncogenic transcription factor FOXM1 and anticancer therapy. Cell Cycle. 2012; 11(18):3341-3342.
97. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF, Costa RH and Raychaudhuri P. FoxM1, a critical regulator of oxidative stress during oncogenesis. Embo J. 2009; 28(19):2908-2918.
98. Kamarajugadda S, Cai Q, Chen H, Nayak S, Zhu J, He M, Jin Y, Zhang Y, Ai L, Martin SS, Tan M and Lu J. Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis. Cell Death Dis. 2013; 4:e504.
99. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475(7354):106-109.
100. Behren A, Muhlen S, Acuna Sanhueza GA, Schwager C, Plinkert PK, Huber PE, Abdollahi A and Simon C. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene. 2010; 29(10):1519-1530.
101. Wang IC, Snyder J, Zhang Y, Lander J, Nakafuku Y, Lin J, Chen G, Kalin TV, Whitsett JA and Kalinichenko VV. Foxm1 mediates cross talk between Kras/mitogen-activated protein kinase and canonical Wnt pathways during development of respiratory epithelium. Mol Cell Biol. 2012; 32(19):3838-3850.
102. Bhat UG, Halasi M and Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS One. 2009; 4(8):e6593.
103. Halasi M, Pandit B, Wang M, Nogueira V, Hay N and Gartel AL. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth. The American journal of pathology. 2013; 183(1):257-265.
104. Halasi M, Wang M, Chavan TS, Gaponenko V, Hay N and Gartel AL. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem J. 2013; 454(2):201-208.
105. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P and Costa RH. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004; 18(7):830-850.
106. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P and Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011; 20(5):620-634.
107. Kortuem KM and Stewart AK. Carfilzomib. Blood. 2013; 121(6):893-897.
108. Reinstein E and Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Annals of internal medicine. 2006; 145(9):676-684.
109. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012; 12(2):121-132.
110. Chang CP, Su YC, Hu CW and Lei HY. TLR2-dependent selective autophagy regulates NF-kappaB lysosomal degradation in hepatoma-derived M2 macrophage differentiation. Cell death and differentiation. 2013; 20(3):515-523.
111. DiDonato JA, Mercurio F and Karin M. NF-kappaB and the link between inflammation and cancer. Immunological reviews. 2012; 246(1):379-400.
112. Morgan MJ and Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011; 21(1):103-115.
113. Lu SC. Regulation of glutathione synthesis. Molecular aspects of medicine. 2009; 30(1-2):42-59.
114. Lin Y, Bai L, Chen W and Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert opinion on therapeutic targets. 2010; 14(1):45-55.
115. Ahmed KM and Li JJ. ATM-NF-kappaB connection as a target for tumor radiosensitization. Current cancer drug targets. 2007; 7(4):335-342.
116. D'Anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, Di Marco P, Emanuele S, Di Fiore R, Guercio A, Vento R and Tesoriere G. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell death&disease. 2013; 4:e891.
117. Shen HM and Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis: an international journal on programmed cell death. 2009; 14(4):348-363.
118. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A and Yamashita S. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology. 2008; 149(11):5357-5365.
119. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, Tasaka K and Murata Y. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem. 2004; 279(22):23477-23485.
120. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K and Murata Y. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004; 10(22):7645-7654.
121. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH and Huang P. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell death and differentiation. 2013; doi: 10.1038/cdd.2013.131. Epub 2013 Oct 4.
122. Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, Dipaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN and Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell death&disease. 2013; 4:e877.
123. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P and Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009; 461(7260):109-113.
124. Velletri T, Romeo F, Tucci P, Peschiaroli A, Annicchiarico-Petruzzelli M, Niklison-Chirou MV, Amelio I, Knight RA, Mak TW, Melino G and Agostini M. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle. 2013; 12(22).
125. Dotsch V, Bernassola F, Coutandin D, Candi E and Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol. 2010; 2(9):a004887.
126. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, Melino G and Knight RA. p73 in Cancer. Genes&cancer. 2011; 2(4):491-502.
127. McCubrey JA and Demidenko ZN. Recent discoveries in the cycling, growing and aging of the p53 field. Aging. 2012; 4(12):887-893.
128. Amelio I, Grespi F, Annicchiarico-Petruzzelli M and Melino G. p63 the guardian of human reproduction. Cell Cycle. 2012; 11(24):4545-4551.
129. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M and Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol. 2013; 15(8):991-1000.
130. Hamilton NM, Dawson M, Fairweather EE, Hamilton NS, Hitchin JR, James DI, Jones SD, Jordan AM, Lyons AJ, Small HF, Thomson GJ, Waddell ID and Ogilvie DJ. Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. J Med Chem. 2012; 55(9):4431-4445.
131. Traba J, Del Arco A, Duchen MR, Szabadkai G and Satrustegui J. SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2+) buffering. Cell death and differentiation. 2012; 19(4):650-660.
132. Willier S, Butt E and Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biology of the cell / under the auspices of the European Cell Biology Organization. 2013; 105(8):317-333.
133. Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC and Zlotnik A. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006; 7(2):67-80.
134. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-264.
135. Grunewald TG, Willier S, Janik D, Unland R, Reiss C, da Costa OP, Buch T, Dirksen U, Richter GH, Neff F, Burdach S and Butt E. The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth. Biology of the cell / under the auspices of the European Cell Biology Organization. 2013; 105(11):535-547, doi: 10.1111/boc.201300041
136. Miller IV, Raposo G, Welsch U, Prazeres da Costa O, Thiel U, Lebar M, Maurer M, Bender HU, von Luettichau I, Richter GH, Burdach S and Grunewald TG. First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biology of the cell / under the auspices of the European Cell Biology Organization. 2013; 105(7):289-303.
137. Bentley AR, Emrani P and Cassano PA. Genetic variation and gene expression in antioxidant related enzymes and risk of COPD: a systematic review. Thorax. 2008; 63(11):956-961.